Will taking giritinib (segatan) cause bone and joint pain and how to deal with it

Gilteritinib is an oral FLT3 tyrosine kinase inhibitor mainly used to treat patients with acute myeloid leukemia (AML) with FLT3 mutations. Clinical studies have shown that giritinib is generally well tolerated, but some non-hematological side effects may still occur. Among them, bone and joint pain and muscle soreness are common symptoms reported by some patients, especially in the early stages of treatment.

Bone and joint pain may be related to the indirect effects of giritinib on the bone marrow environment and inflammatory response after inhibiting the FLT3 signaling pathway. Drug intervention may cause temporary changes in hematopoietic activity and bone metabolic balance in the bone marrow, coupled with fluctuations in white blood cell levels and adjustments in the immune system, easily causing mild discomfort in muscles, joints or bones. Usually, this type of pain is mild to moderate and can resolve on its own, but in a few patients it may affect daily life.

Countermeasures:
1. Symptomatic treatment: Over-the-counter analgesics (such as acetaminophen) can be used to relieve mild soreness, but you need to follow the doctor's guidance and pay attention to the liver and kidney function.
2. Lifestyle adjustments: Moderate exercise, hot compress or mild stretching can help relieve joint stiffness and soreness, while maintaining adequate rest.
3. Monitor symptoms: Record the intensity and duration of pain. If severe joint swelling or limited movement occurs, seek medical attention promptly to investigate other causes.
During treatment with giritinib, patients should be followed up regularly to monitor blood routine and bone marrow recovery, and communicate with the attending doctor about soreness. For moderate to severe pain that affects quality of life, dose adjustment or combined symptomatic treatment may be considered. Through scientific management, most bone and joint pain can be effectively relieved, while ensuring the anti-leukemia efficacy of giritinib and achieving safe and long-term treatment effects.
Reference: https://www.drugs.com/